A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 700
- Locations
- 1
- Primary Endpoint
- CT-based radiomics analysis for benign and malignant tumor differentiation
Study Overview
Brief Summary
To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma).
- •Contrast-enhanced CT scan was performed preoperatively.
Exclusion Criteria
- •Pure cystic clear cell renal cell carcinoma
- •Poor-quality CT images
Outcomes
Primary Outcomes
CT-based radiomics analysis for benign and malignant tumor differentiation
Time Frame: within 1 month
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma
CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC)
Time Frame: within 1 month
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC
CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC)
Time Frame: within 1 month
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC
Secondary Outcomes
No secondary outcomes reported